(19)
(11) EP 3 383 386 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.03.2024 Bulletin 2024/12

(45) Mention of the grant of the patent:
14.02.2024 Bulletin 2024/07

(21) Application number: 16867098.2

(22) Date of filing: 17.11.2016
(51) International Patent Classification (IPC): 
A61K 31/341(2006.01)
A61P 35/00(2006.01)
 C07C 225/20(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61K 31/341; A61K 31/4035; A61K 31/4155; A61K 31/4439; A61K 31/454; A61K 31/4725; A61K 31/506; A61K 45/06; C07D 209/46; C07D 307/52; C07D 405/12; C07D 405/14
(86) International application number:
PCT/US2016/062417
(87) International publication number:
WO 2017/087607 (26.05.2017 Gazette 2017/21)

(54)

MODULATORS OF CHEMOKINE RECEPTORS

MODULATOREN VON CHEMOKINREZEPTOREN

MODULATEURS DES RÉCEPTEURS DES CHIMIOKINES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 19.11.2015 US 201562257389 P
12.01.2016 US 201662277711 P

(43) Date of publication of application:
10.10.2018 Bulletin 2018/41

(73) Proprietor: ChemoCentryx, Inc.
Thousand Oaks, CA 91320 (US)

(72) Inventors:
  • CHEN, Xi
    E. Palo Alto, CA 94303 (US)
  • DRAGOLI, Dean, R.
    Los Altos, CA 94024 (US)
  • FAN, Junfa
    Palo Alto, CA 94306 (US)
  • KALISIAK, Jaroslaw
    Mountain View, CA (US)
  • KRASINSKI, Antoni
    Sunnyvale, CA 94087 (US)
  • LELETI, Manmohan, Reddy
    Dublin, CA 94568 (US)
  • MALI, Venkat
    Cupertino, CA 95014 (US)
  • MCMAHON, Jeffrey
    San Francisco, CA 94121 (US)
  • SINGH, Rajinder
    Belmont, CA 94002 (US)
  • TANAKA, Hiroko
    Mountain View, CA 94041 (US)
  • YANG, Ju
    Palo Alto, CA 94303 (US)
  • YU, Chao
    Sunnyvale, CA 94086 (US)
  • ZHANG, Penglie
    Foster City, CA 94404 (US)

(74) Representative: HGF 
HGF Limited 1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)


(56) References cited: : 
WO-A1-02/083624
WO-A1-2013/061005
US-A1- 2008 261 917
US-A1- 2011 213 029
 WO-A1-2007/014608
WO-A1-2017/087610
US-A1- 2010 267 712
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).